1,720
Participants
Start Date
March 7, 2024
Primary Completion Date
June 27, 2025
Study Completion Date
August 8, 2027
KLU156
Oral use. KLU156 (400/480 mg) is the dose for patients with a bodyweight ≥ 35kg. Patients \< 35kg will take a fraction of the dose according to weight group as defined in the protocol.
Coartem
Oral use. Dosing will be selected based on patient's body weight as per product's label.
Novartis Investigative Site, Siaya
Novartis Investigative Site, Tanga
Novartis Investigative Site, Niamey
Novartis Investigative Site, Tororo
Novartis Investigative Site, Kombewa
Novartis Investigative Site, Nchelenge
Novartis Investigative Site, Ndola
Novartis Investigative Site, Kintampo
Novartis Investigative Site, Bhubaneswar
Novartis Investigative Site, Banfora
Novartis Investigative Site, Kimpese
Novartis Investigative Site, Kisantu
Novartis Investigative Site, Commune de La Kenya Lubumbashi
Novartis Investigative Site, Kenge
Novartis Investigative Site, Masi-Manimba
Novartis Investigative Site, Sotouba
Novartis Investigative Site, Rubavu
Novartis Investigative Site, Rusizi
Novartis Investigative Site, Bagamoyo
Novartis Investigative Site, Korogwe Tanga
Novartis Investigative Site, Bobo-Dioulasso
Novartis Investigative Site, Nanoro
Novartis Investigative Site, Ouagadougou
Novartis Investigative Site, Sabou
Novartis Investigative Site, Abidjan
Novartis Investigative Site, Agboville
Novartis Investigative Site, Azaguié
Novartis Investigative Site, Lambaréné
Novartis Investigative Site, Libreville
Novartis Investigative Site, Navrango
Novartis Investigative Site, Nairobi
Novartis Investigative Site, Gicumbi District Rwamiko
Novartis Investigative Site, Kigali
Novartis Investigative Site, Kigali
Lead Sponsor
MMV, EDCTP, WANECAM
UNKNOWN
Novartis Pharmaceuticals
INDUSTRY